Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Shots:

• The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations
• The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases
• Sanofi provides seed funding to i20 in Apr’2020 while the company received strategic investment from Colorcon Ventures in Dec’2020

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire